Abstract:What's new? Circulating tumor DNA (ctDNA) contains genetic mutations specific to the tumor, but not all mutations work equally well as ctDNA markers. Here, the authors show that choosing mutations based on three key features—cancer cell fraction, error rate, and multiplicity—gave the best success in detecting ctDNA. They also make available a bioinformatic pipeline that can be used to extract these key features, which will help streamline the selection of the most promising mutations for ctDNA testing. Tumor‐informed mutation‐based approaches are frequently used for detection of circulating tumor DNA (ctDNA). Not all mutations make equally effective ctDNA markers. The objective was to explore if prioritizing mutations using mutational features—such as cancer cell fraction (CCF), multiplicity, and error rate—would improve the success rate of tumor‐informed ctDNA analysis. Additionally, we aimed to develop a practical and easily implementable analysis pipeline for identifying and prioritizing candidate mutations from whole‐exome sequencing (WES) data. We analyzed WES and ctDNA data from three tumor‐informed ctDNA studies, one on bladder cancer (Cohort A) and two on colorectal cancer (Cohorts I and N). The studies included 390 patients. For each patient, a unique set of mutations (median mutations/patient: 6, interquartile 13, range: 1–46, total n = 4023) were used as markers of ctDNA. The tool PureCN was used to assess the CCF and multiplicity of each mutation. High‐CCF mutations were detected more frequently than low‐CCF mutations (Cohort A: odds ratio [OR] 20.6, 95% confidence interval [CI] 5.72–173, p = 1.73e−12; Cohort I: OR 2.24, 95% CI 1.44–3.52, p = 1.66e−04; and Cohort N: OR 1.78, 95% CI 1.14–2.79, p = 7.86e−03). The detection‐likelihood was additionally improved by selecting mutations with multiplicity of two or above (Cohort A: OR 1.55, 95% CI 1. 14–2.11, p = 3.85e−03; Cohort I: OR 1.78, 95% CI 1.23–2.56, p = 1.34e−03; and Cohort N: OR 1.94, 95% CI 1.63–2.31, p = 2.83e−14). Furthermore, selecting the mutations for which the ctDNA detection method had the lowest error rates, additionally improved the detection‐likelihood, particularly evident when plasma cell‐free DNA tumor fractions were below 0.1% (p = 2.1e−07). Selecting mutational markers with high CCF, high multiplicity, and low error rate significantly improve ctDNA detection likelihood. We provide free access to the analysis pipeline enabling others to perform qualified prioritization of mutations for tumor‐informed ctDNA analysis.

Machine learning enables pan-cancer identification of mutational hotspots at persistent CTCF binding sites

DeepCBS: shedding light on the impact of mutations occurring at CTCF binding sites

Brain and cancer associated binding domain mutations provide insight into CTCF′s relationship with chromatin and its contribution to gene regulation

Systematical Identification of Cell-Specificity of CTCF-gene Binding Based on Epigenetic Modifications.

CTCF Loss Mediates Unique DNA Hypermethylation Landscapes in Human Cancers

A Multi-Omics Analysis Reveals CLSPN is Associated with Prognosis, Immune Microenvironment and Drug Resistance in Cancers

CTCF: A misguided jack-of-all-trades in cancer cells

Inferring CTCF-binding Patterns and Anchored Loops Across Human Tissues and Cell Types

Structure–function relationships explain CTCF zinc finger mutation phenotypes in cancer

Predicting CTCF’s Cell Type-Specific Binding Sites in Human Genome

Intra-clustering analysis reveals tissue-specific mutational patterns

Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer

Chromatin accessibility contributes to simultaneous mutations of cancer genes

Machine learning predictions improve identification of real-world cancer driver mutations

Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis

Cancer somatic mutations cluster in a subset of regulatory sites predicted from the ENCODE data

Comprehensive analysis of cancer breakpoints reveals signatures of genetic and epigenetic contribution to cancer genome rearrangements

Multi-level characteristics recognition of cancer core therapeutic targets and drug screening for a broader patient population

Single-cell chromatin accessibility reveals malignant regulatory programs in primary human cancers

Mutational landscape and significance across 12 major cancer types

Beyond basics: Key mutation selection features for successful tumor‐informed ctDNA detection